摘要
Immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized the treatment of many types of cancer, particularly advanced-stage cancers. Nevertheless, although a subset of patients experiences dramatic and long-term disease regression in response to ICIs, most patients do not benefit from these treatments. Some may even experience cancer progression. Immune escape by tumor cells may be a key reason for this low response rate. N-6-methyladenosine (m(6)A) is the most common type of RNA methylation and has been recognized as a critical regulator of tumors and the immune system. Therefore, m(6)A modification and related regulators are promising targets for improving the efficacy of tumor immunotherapy. However, the association between m(6)A modification and tumor immune escape (TIE) has not been comprehensively summarized. Therefore, this review summarizes the existing knowledge regarding m(6)A modifications involved in TIE and their potential mechanisms of action. Moreover, we provide an overview of currently available agents targeting m(6)A regulators that have been tested for their elevated effects on TIE. This review establishes the association between m(6)A modifications and TIE and provides new insights and strategies for maximizing the efficacy of immunotherapy by specifically targeting m(6)A modifications involved in TIE.
学科与关键词
- Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapyLiu, Weiwei; Liu, Chaoqun; Wang, Hui; Xu, Lijun; Zhou, Jueyu; Li, Sihua; Cheng, Yu; Zhou, Rui*; Zhao, Liang*Computational and Structural Biotechnology Journal, 2022, 20: 5150-5161.被引 5
- N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of MelanomaWang, Gaofeng; Zeng, Dongqiang; Sweren, Evan; Miao, Yong; Chen, Ruosi; Chen, Junjun; Wang, Jin; Liao, Wangjun; Hu, Zhiqi; Kang, Sewon; Garza, Luis A.*Journal of Investigative Dermatology, 2023, 143(8).被引 1
- N6-methyladenosine RNA modifications: a potential therapeutic target for AMLHu, Rong; Liao, Peiyun; Xu, Binyan; Qiu, Yingqi; Zhang, Honghao; Li, Yuhua*Annals of Hematology, 2023.
